Page last updated: 2024-12-05

methazolamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4100
CHEMBL ID288100
CHEMBL ID19
CHEMBL ID1335656
CHEBI ID6822
CHEBI ID94513
SCHEMBL ID24687
SCHEMBL ID24686
SCHEMBL ID13825893
MeSH IDM0013561

Synonyms (193)

Synonym
MLS001146905
n-(3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene)acetamide
BRD-K71053238-001-03-6
BRD-K71053238-001-04-4
acetamide, n-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene]-
smr000058287
DIVK1C_000582
KBIO1_000582
BSPBIO_000663
n-[(2e)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene]acetamide
metazolamida [inn-spanish]
5-acetylimino-4-methyl-delta(sup 2)-1,3,4-thiadiazoline-2-sulfonamide
acetamide, n-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene)-
acetamide, n-(4-methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)-
2-acetylimino-3-methyl-delta(sup 4)-1,3,4-thiadiazoline-5-sulfonamide
metazolamide [dcit]
n-(4-methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)acetamide
methazolamidum [inn-latin]
hsdb 3269
einecs 209-066-7
brn 0232387
neptazane
SPECTRUM_001615
methenamide
PRESTWICK_1007
cas-554-57-4
NCGC00016508-01
IDI1_000582
BSPBIO_003508
PRESTWICK2_000802
OPREA1_161738
PRESTWICK3_000802
AB00490015
methazolamide
554-57-4
C07764
n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3h)-ylidene)acetamide
n-[(2z)-3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene]acetamide
neptazaneat
DB00703
bdbm10881
methazolamide (mza)
methazolamide, mza
cid_4100
mza3
chembl288100 ,
methazolamide (jan/usp/inn)
D00655
neptazane (tn)
SPECTRUM5_001006
BPBIO1_000731
NCGC00022950-04
NCGC00022950-03
MLS000028532 ,
KBIO2_002095
KBIO2_004663
KBIO2_007231
KBIOSS_002095
KBIOGR_000739
KBIO3_003013
PRESTWICK0_000802
NINDS_000582
SPBIO_002584
SPECTRUM3_001914
SPECTRUM2_001543
SPBIO_001386
PRESTWICK1_000802
SPECTRUM4_000190
SPECTRUM1503252
NCGC00178022-02
NCGC00178022-01
NCGC00018188-01
HMS2093A05
l-584601
CHEMBL19
chebi:6822 ,
vvp808
nsc-758426
vvp-808
HMS501N04
HMS1922M19
HMS1570B05
n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide
bdbm50013792
NCGC00018188-02
NCGC00018188-05
NCGC00018188-04
NCGC00018188-06
NCGC00018188-07
NCGC00018188-03
HMS3259H05
HMS2097B05
n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)ethanamide
A830656
nsc758426
pharmakon1600-01503252
tox21_110464
dtxsid1023281 ,
dtxcid503281
HMS2234L03
CCG-39321
naptazane
4-27-00-08221 (beilstein handbook reference)
methazolamidum
unii-w733b0s9sd
metazolamida
nsc 758426
methazolamide [usp:inn:ban:jan]
w733b0s9sd ,
metazolamide
methazolamide [inn]
methazolamide [hsdb]
methazolamide [orange book]
methazolamide [vandf]
acetamide, n-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene]-, [n(e)]-
methazolamide [who-dd]
methazolamide [usp monograph]
methazolamide [jan]
methazolamide [usp-rs]
methazolamide [mart.]
[n(e)]-n-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene]acetamide
methazolamide [mi]
n-(4-methyl-2-sulfamoyl-.delta.(sup 2)-1,3,4-thiadiazolin-5-ylidene)acetamide
2101958-72-7
AKOS015897587
gtpl6828
HMS3372G12
HY-B0553
NC00618
SCHEMBL24687
SCHEMBL24686
KS-5328
CHEMBL1335656
SCHEMBL13825893
FLOSMHQXBMRNHR-DAXSKMNVSA-N
acetamide, n-(4-methyl-2-sulfamoyl-.delta.2-1,3,4-thiadiazolin-5-ylidene)-
n-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene)acetamide #
n-(4-methyl-2-sulfamoyl-.delta.2-1,3,4-thiadiazolin-5-ylidene)acetamide
FLOSMHQXBMRNHR-UHFFFAOYSA-N
2-acetylimino-3-methyl-.delta.(4)-1,3,4-thiadiazoline-5-sulfonamide
5-acetylimino-4-methyl-.delta.(2)-1,3,4-thiadiazoline-2-sulfonamide
AC-32472
AKOS024464790
OPERA_ID_717
AB00052336_04
acetamide, n-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene)-, (n(z))-
unii-da43gw06p1
methazolamide, (z)-
1164547-86-7
DA43GW06P1 ,
AKOS026749792
cl 8490
l584601
SR-05000001844-3
sr-05000001844
methazolamide, united states pharmacopeia (usp) reference standard
methazolamide, vetranal(tm), analytical standard
CHEBI:94513
HMS3652E21
SR-05000001844-2
SR-05000001844-1
methazolamide, >=98% (hplc)
SBI-0051804.P002
HMS3714B05
n-[(2e)-3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene]acetamide
SW197085-3
(e)-n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3h)-ylidene
S4039
FLOSMHQXBMRNHR-QPJJXVBHSA-N
mfcd00083416
methazolamide,(s)
(e)-n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3h)-ylidene)acetamide
AS-13272
Q1149099
BRD-K13356952-001-15-2
bdbm315269
us10172837, methazolamide
SB17307
NCGC00016508-18
(ne)-n-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide
HMS3747O09
CCG-266836
NCGC00016508-04
(z)-methazolamide
Q27276292
D81966
DTXSID50901331
noname_433
n-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3h)-ylidene]acetamide;
NCGC00016508-03
EN300-51717
EN300-7412532
Z728800602

Research Excerpts

Overview

Methazolamide is an intraocular pressure-lowering drug that is used in the treatment of glaucoma and other ophthalmologic abnormalities. There are many side effects of its systemic administration with insufficient ocular therapeutic concentrations.

ExcerptReferenceRelevance
"Methazolamide is an important carbonic anhydrase inhibitor and is mainly used for the treatment of glaucoma. "( Detection, identification, characterization, and high-performance liquid chromatography quantification of five impurities from a methazolamide product.
He, Q; Pan, Y; Shen, Q; Sun, C, 2022
)
2.37
"Methazolamide is a carbonic anhydrase (CA) inhibitor with satisfactory safety. "( Revealing mechanism of Methazolamide for treatment of ankylosing spondylitis based on network pharmacology and GSEA.
Gao, P; Liang, W; Liu, Q; Sun, T; Wang, M; Yan, X, 2023
)
2.66
"Methazolamide (MTZ) is an anti-glaucoma drug exhibiting poor corneal penetration, making it an ideal candidate for new polymeric micellar systems."( Exploring optimized methoxy poly(ethylene glycol)-block-poly(ε-caprolactone) crystalline cored micelles in anti-glaucoma pharmacotherapy.
Biondo, F; Casettari, L; Elmowafy, E; Gad, H; Soliman, ME, 2019
)
1.24
"Methazolamide (MTZ) is an anti-glaucoma drug. "( Preformulation study of methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions.
Guo, Z; Jiang, S; Li, R; Wang, F; Xu, Q; Zhang, X; Zhu, S, 2013
)
2.14
"Methazolamide is an intraocular pressure-lowering drug that is used in the treatment of glaucoma and other ophthalmologic abnormalities. "( HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese.
Cao, Z; Chen, J; Chen, S; He, L; Luo, H; Luo, X; Sun, X; Xing, Q; Xuan, J; Yang, F; Zhong, H; Zhou, P, 2016
)
2.1
"Methazolamide (MTA) is an antiglaucoma drug; however, there are many side effects of its systemic administration with insufficient ocular therapeutic concentrations. "( A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide.
Bi, X; Jiang, S; Li, R; Liu, D; Wang, F; Xu, Q; Zhang, Q, 2011
)
2.04
"Methazolamide is a carbonic anhydrase inhibitor used to treat glaucoma. "( Determination of methazolamide concentrations in human biological fluids using high performance liquid chromatography.
Iyer, GR; Taft, DR, 1998
)
2.08

Effects

ExcerptReferenceRelevance
"Methazolamide has only limited efficacy in the treatment of essential tremor."( Double-blind controlled study of methazolamide in the treatment of essential tremor.
Busenbark, K; Hopfensperger, K; Hubble, J; Koller, W; Pahwa, R; Pogrebra, K, 1993
)
1.29

Actions

Methazolamide and melatonin inhibit oxygen/glucose deprivation-induced cell death, loss of mitochondrial membrane potential, release of mitochondrial factors, pro-IL-1beta processing, and activation of caspase-1 and -3.

ExcerptReferenceRelevance
"Methazolamide can increase systemic metabolic acidosis and sequentially improve ventilation and oxygenation level."( Methazolamide in high-altitude illnesses.
Jiang, Y; Lu, H; Zhang, H, 2020
)
2.72
"Methazolamide is used to lower intraocular pressure in patients with glaucoma. "( Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01.
Dong, Q; Mao, X; Shu, C; Shu, D; Sun, Q; Tie, D; Wang, T; Yan, Y; Yu, M; Zhang, R, 2015
)
2.13
"Methazolamide and melatonin inhibit oxygen/glucose deprivation-induced cell death, loss of mitochondrial membrane potential, release of mitochondrial factors, pro-IL-1beta processing, and activation of caspase-1 and -3 in primary cerebrocortical neurons. "( Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury.
Day, AL; Figueroa, BE; Friedlander, RM; Kristal, BS; Sirianni, AC; Stavrovskaya, IG; Wang, X; Zhang, Y; Zhu, S, 2009
)
3.24

Treatment

ExcerptReferenceRelevance
"Methazolamide treatment was associated with a ΔHbA1c of -0.39% (95% CI -0.82, 0.04; P < 0.05) (-4.3 mmol/mol [-9.0, 0.4]), an increase in the proportion of patients achieving HbA1c ≤6.5% (48 mmol/mol) from 8 to 33%, a rapid reduction in alanine aminotransferase (∼10 units/L), and weight loss (2%) in metformin-cotreated patients."( Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study.
Chambers, J; Krippner, G; MacGinley, R; Nicholson, GC; Orford, N; Phillips, G; Proietto, J; Sanders, KM; Sarah, A; Simpson, RW; Skoff, K; Wacher, VJ; Walder, K, 2014
)
1.42

Pharmacokinetics

ExcerptReferenceRelevance
" The proposed method was successfully applied to study the pharmacokinetic interaction between MT and methazolamide."( Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide.
Abdel-Wadood, HM; Emara, KM; Hassan, MG; Ikeda, R; Kuroda, N; Mohamed, HA; Nakashima, K; Wada, M, 2012
)
0.79
"In the present era of drug development, quantification of drug concentrations following pharmacokinetic studies has preferentially been performed using plasma as a matrix rather than whole blood."( Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection?
Dash, RP; Mehta, N; Rosenfeld, C; Srinivas, NR; Thomas, JA; Veeravalli, V, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"The multiple drug interactions in which CAIs are involved should be carefully considered when such drugs are used in combination with the drug classes mentioned above, as the risks of developing toxicity and serious side effects if the dosages are not adjusted are high."( Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.
Supuran, CT, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Furthermore, the bioavailability of these derivatives in rabbits is comparable to that of acetazolamide, being in the range of 85-90%, showing them as promising candidates for systemically acting CA inhibitors."( Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
Scozzafava, A; Supuran, CT, 2002
)
0.31
"In this study, a thermosensitive in situ gelling vehicle was prepared to increase the precorneal resident time and the bioavailability of methazolamide (MTA)."( Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide.
Li, R; Qian, Y; Wang, F; Xu, Q; Zhang, Q, 2010
)
0.79
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Solid lipid nanoparticles and nanostructured lipid carriers showed promising results for enhancement of ocular bioavailability of drugs with poor corneal permeability."( Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs.
El Shamy, A; Kamel, AO; Mansour, S; Youshia, J, 2021
)
0.62

Dosage Studied

The Peaks A and B were isolated from the urine of the animals dosed with non-radioactive methazolamide. On angiography, nine subjects demonstrated improvement in their macular edema. Three of these continued receiving the drug at a dosage of 50 mg twice daily for an additional 6 (one subject) or 12 (two subjects) weeks.

ExcerptRelevanceReference
" The mean reduction in outflow pressure for all eyes receiving a daily dosage of 300 mg was only 31%, but this included eyes (17% of the total) that demonstrated less than 13% reduction in outflow pressure, despite similar methazolamide serum levels."( A repeated dose-response study of methazolamide in glaucoma.
Dahlen, K; Epstein, DL; Grant, WM; Hutchinson, BT; Krall, JM; Prien, EL, 1978
)
0.72
" In addition, there is a close relationship between the dose-response curves for 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid inhibition of VA taurine efflux and sulfate efflux."( Volume-activated taurine efflux from skate erythrocytes: possible band 3 involvement.
Brill, SR; Goldstein, L, 1991
)
0.28
" Dosage and time effects were also determined."( Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma.
Lichter, PR; Medzihradsky, F; Musch, DC; Standardi, CL, 1989
)
0.28
" At the concentration and dosage employed here there was no significant difference between the hypotensive effects of timolol and TFM."( The effects of separate and combined topical treatment with timolol maleate and trifluormethazolamide on the intraocular pressure in normal rabbits.
Bar-Ilan, A, 1984
)
0.49
" Other than switching drugs to reduce CAI side effects, one can try reduced dosages, a gradual dosage increase, and patience."( Reducing side effects of carbonic anhydrase inhibitors.
Lichter, PR, 1981
)
0.26
" On angiography, nine subjects demonstrated improvement in their macular edema with the use of methazolamide for 3 weeks; three of these continued receiving the drug at a dosage of 50 mg twice daily for either an additional 6 (one subject) or 12 (two subjects) weeks."( Rebound of macular edema with continued use of methazolamide in patients with retinitis pigmentosa.
Fishman, GA; Gilbert, LD; Glenn, AM, 1993
)
0.76
"8 mmHg by 2 min) and aqueous flow (33% and 40% by 5 min) following intravenous dosing with either methazolamide or ethoxzolamide."( A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion.
Brechue, WF; Maren, TH, 1993
)
0.5
" A dose-effect relationship that is the reduction of intraocular pressure increases with the increase of the dosage administration of methazolamide could be observed."( [An experimental study on effect of methazolamide on decreasing intraocular pressure in rabbits].
Xu, H; Yao, Q; Zhou, G, 1999
)
0.78
" However, their short duration of action requiring multiple daily dosing can hamper patient compliance."( Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension.
Bas, JF; Jansook, P; Kristjánsdóttir, SS; Loftsson, T; Sigurdsson, BB; Sigurdsson, HH; Stefánsson, E; Thorsteinsdóttir, M, 2010
)
0.36
" The Peaks A and B were isolated from the urine of the animals dosed with non-radioactive methazolamide."( The metabolism of methazolamide - identification of metabolites in guinea pig urine.
Iwai, Y; Kishida, K; Kuhara, M; Sakamoto, Y; Sasabe, T; Yamamura, N, 2011
)
0.92
" The chosen dependent variables were entrapment efficiency, dosage loading, and particle size."( Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design.
Chen, L; He, J; Jiang, S; Li, R; Peng, J; Wang, F; Xu, Q; Zhang, X, 2014
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
thiadiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (65)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency15.84890.025120.237639.8107AID886
phosphopantetheinyl transferaseBacillus subtilisPotency29.30430.141337.9142100.0000AID1490; AID2701
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID743255
Microtubule-associated protein tauHomo sapiens (human)Potency3.98110.180013.557439.8107AID1468
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.75090.035520.977089.1251AID504332
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
huntingtin isoform 2Homo sapiens (human)Potency12.58930.000618.41981,122.0200AID1688
Cellular tumor antigen p53Homo sapiens (human)Potency12.74480.002319.595674.0614AID651631
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency26.85450.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase Astrosclera willeyanaKi0.32600.03201.51729.6000AID644379
corticotropin-releasing hormone receptor 2Homo sapiens (human)IC50 (µMol)47.10000.36807.095518.0000AID602180
Carbonic anhydrase Sulfurihydrogenibium sp. YO3AOP1Ki0.00820.00450.16240.8760AID1268964
Carbonic anhydrase Stylophora pistillataKi0.02120.00000.686710.0000AID436565; AID552130
Carbonic anhydraseStylophora pistillataKi0.13200.00000.50715.7100AID552131
corticotropin releasing factor-binding proteinHomo sapiens (human)IC50 (µMol)47.10000.36807.095518.0000AID602180
Carbonic anhydraseHelicobacter pylori 26695Ki0.19800.02000.54864.3600AID261581; AID263638
Carbonic anhydrase 12Homo sapiens (human)IC50 (µMol)0.02000.00571.39908.5700AID50185
Carbonic anhydrase 12Homo sapiens (human)Ki4.80730.00021.10439.9000AID1062684; AID1067227; AID1154448; AID1204091; AID1347714; AID1379906; AID1593068; AID1796980; AID1798598; AID1799734; AID238316; AID238439; AID239126; AID239284; AID258733; AID271040; AID272527; AID293193; AID311032; AID321159; AID327767; AID367617; AID417834; AID486935; AID512004; AID614108; AID770582
Prolyl endopeptidaseRattus norvegicus (Norway rat)Ki0.06500.00000.10840.6300AID578223
Glycogen phosphorylase, muscle formOryctolagus cuniculus (rabbit)Ki0.04300.02504.89039.0000AID614109
Tyrosine-protein kinase ABL1Homo sapiens (human)IC50 (µMol)0.01400.00010.712810.0000AID1799511
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)0.04690.00582.14107.9000AID50185; AID50344; AID50345; AID734185
Carbonic anhydrase 1Homo sapiens (human)Ki1.71470.00001.372610.0000AID1062687; AID1067230; AID1140817; AID1142833; AID1154445; AID1188134; AID1190063; AID1194024; AID1195369; AID1262263; AID1268962; AID1275913; AID1287517; AID1347711; AID1379902; AID1434427; AID1453412; AID1593065; AID1628036; AID1796552; AID1796595; AID1796755; AID1796855; AID1796980; AID1797276; AID1797360; AID1797528; AID1798598; AID1798769; AID1799673; AID1799734; AID222125; AID238085; AID238208; AID238211; AID238247; AID238276; AID238309; AID238409; AID238536; AID238620; AID238753; AID238760; AID238761; AID238770; AID238830; AID238957; AID239223; AID254240; AID258729; AID261579; AID263636; AID271037; AID271172; AID271710; AID272520; AID275807; AID281082; AID287698; AID300867; AID311023; AID317579; AID321156; AID327758; AID331498; AID349605; AID367608; AID367820; AID369271; AID414955; AID417825; AID427125; AID436563; AID47709; AID47710; AID486932; AID50350; AID50351; AID50352; AID50353; AID50354; AID50355; AID50356; AID50357; AID50362; AID50364; AID50366; AID50371; AID50373; AID50375; AID50377; AID50378; AID50379; AID50380; AID512001; AID552127; AID577526; AID578221; AID587130; AID603067; AID612725; AID614105; AID644380; AID725955; AID743515; AID764719; AID770586
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)0.03470.00021.10608.3000AID1796686; AID1799511; AID47732; AID47736; AID47748; AID47749; AID47750; AID50185; AID734184
Carbonic anhydrase 2Homo sapiens (human)Ki1.45820.00000.72369.9200AID1061069; AID1062686; AID1067229; AID1140816; AID1142834; AID1154446; AID1188135; AID1190064; AID1194025; AID1195370; AID1240217; AID1262264; AID1268963; AID1275912; AID1278409; AID1287518; AID1347712; AID1379904; AID1434428; AID1453413; AID1593066; AID1628037; AID1796552; AID1796582; AID1796595; AID1796755; AID1796855; AID1796980; AID1797276; AID1797360; AID1797528; AID1798598; AID1798769; AID1799586; AID1799673; AID1799734; AID222126; AID238084; AID238220; AID238223; AID238255; AID238300; AID238323; AID238437; AID238574; AID238635; AID238768; AID238772; AID238773; AID238787; AID238850; AID238852; AID238986; AID239240; AID254241; AID256963; AID258730; AID261580; AID263637; AID271038; AID271173; AID271711; AID272521; AID275808; AID281083; AID287699; AID300868; AID311024; AID317580; AID321157; AID327759; AID331499; AID349606; AID367609; AID367821; AID369272; AID414956; AID417826; AID427124; AID436564; AID437749; AID448552; AID47719; AID47898; AID47899; AID47900; AID47901; AID47902; AID47903; AID47904; AID47905; AID47929; AID47931; AID47936; AID47938; AID47940; AID47942; AID48088; AID48090; AID48091; AID48092; AID48093; AID486933; AID512002; AID552128; AID577527; AID578222; AID587131; AID603068; AID612726; AID614106; AID644381; AID669115; AID725956; AID743514; AID764718; AID770585
Carbonic anhydrase 3Homo sapiens (human)IC50 (µMol)0.02000.02001.66866.5000AID50185
Carbonic anhydrase 3Homo sapiens (human)Ki496.66790.00022.010210.0000AID1798598; AID301578; AID311025; AID327760; AID367610; AID417827; AID603069
Cathepsin BBos taurus (cattle)IC50 (µMol)0.02000.02000.09130.3100AID50185
Cytochrome P450 3A4Homo sapiens (human)Ki0.01520.00011.41629.9000AID1154447; AID1154448
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.01230.00020.667710.0000AID47929; AID47936; AID47942
Dihydrofolate reductaseEscherichia coli K-12IC50 (µMol)0.01400.00150.55126.8000AID1799511
Cytochrome P450 2C9 Homo sapiens (human)Ki0.02700.00031.684210.0000AID1154447
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.01230.00010.601710.0000AID47929; AID47936; AID47942
Carbonic anhydrase 4Homo sapiens (human)IC50 (µMol)0.07920.00320.31712.0000AID1796686; AID50185
Carbonic anhydrase 4Homo sapiens (human)Ki10.05040.00021.97209.9200AID1796980; AID1798598; AID1799673; AID222127; AID238575; AID272522; AID311026; AID327761; AID367611; AID417828
Carbonic anhydrase 6Homo sapiens (human)IC50 (µMol)0.02000.02001.33175.7900AID50185
Carbonic anhydrase 6Homo sapiens (human)Ki18.19590.00011.47109.9200AID1798598; AID1798769; AID275806; AID311029; AID327764; AID367614; AID369273; AID417831; AID552129
Carbonic anhydrase 5A, mitochondrialMus musculus (house mouse)Ki0.24680.00300.45603.0000AID1797528; AID1799673
Cyclin-dependent kinase 2Homo sapiens (human)IC50 (µMol)0.01400.00041.044410.0000AID1799511
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.01230.00020.590910.0000AID47929; AID47936; AID47942
Delta-type opioid receptorMus musculus (house mouse)Ki0.03200.00000.53939.4000AID1188134; AID1188135
Cytochrome P450 2C19Homo sapiens (human)Ki0.00340.00010.830010.0000AID1154448
Delta-type opioid receptorRattus norvegicus (Norway rat)Ki0.00830.00000.60689.2330AID1188135; AID239287
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki0.05000.00000.38458.6000AID1188134
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)IC50 (µMol)0.02000.02003.10819.4000AID50185
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki8.63160.00001.27259.9000AID1796582; AID1796980; AID1798598; AID239287; AID256964; AID272523; AID311027; AID327762; AID367612; AID417829; AID578223
Carbonic anhydraseMethanosarcina thermophilaKi0.15500.06000.97148.5000AID239145; AID239146
Carbonic anhydrase 7Homo sapiens (human)IC50 (µMol)0.02000.02001.21363.4400AID50185
Carbonic anhydrase 7Homo sapiens (human)Ki8.60550.00021.37379.9000AID1796980; AID1798598; AID1799586; AID238256; AID272525; AID311030; AID327765; AID367615; AID417832; AID603070; AID764717; AID770584
Carbonic anhydraseSaccharomyces cerevisiae S288CKi0.11900.08200.56098.7000AID367822
Carbonic anhydrase Mycobacterium tuberculosis H37RvKi0.56200.01202.72389.1200AID448554
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.01400.00000.27869.0000AID1188135
Beta-carbonic anhydrase 1Mycobacterium tuberculosis H37RvKi0.78100.00483.38419.8400AID1798985; AID349607; AID448553
Carbonic anhydrase 2Mycobacterium tuberculosis H37RvKi0.66000.00902.20969.8400AID437750
Carbonic anhydrase 9Homo sapiens (human)IC50 (µMol)0.01580.00030.63029.3900AID48294; AID50185; AID734183
Carbonic anhydrase 9Homo sapiens (human)Ki2.69700.00010.78749.9000AID1062685; AID1067228; AID1154447; AID1347713; AID1379905; AID1593067; AID1796595; AID1796755; AID1796855; AID1796980; AID1797276; AID1797360; AID1798598; AID1798769; AID1799673; AID1799734; AID238083; AID238224; AID238227; AID238438; AID238769; AID238774; AID238788; AID238987; AID239048; AID239102; AID239422; AID254246; AID258732; AID271039; AID271174; AID271712; AID272526; AID275809; AID281084; AID287700; AID300869; AID311031; AID317581; AID321158; AID327766; AID331500; AID367616; AID369274; AID417833; AID48295; AID48296; AID48297; AID48299; AID48300; AID48301; AID48302; AID48303; AID48304; AID48305; AID486934; AID512003; AID614107; AID770583
Carbonic anhydrase, alpha family Hydrogenovibrio crunogenus XCL-2Ki0.02650.00250.32341.1000AID1268965
Carbonic anhydrase Cryptococcus neoformans var. grubiiKi0.06300.01000.73648.3470AID669116
Carbonic anhydraseMethanothermobacter thermautotrophicus str. Delta HKi32.10005.35005.35005.3500AID239250
Carbonic anhydraseCandida albicans SC5314Ki0.37870.01051.44448.3470AID1799266; AID427122; AID669117
Carbonic anhydrase Anopheles gambiae (African malaria mosquito)Ki0.18400.00980.51174.3600AID1195371
Delta carbonic anhydraseConticribra weissflogiiKi0.17000.04960.99789.2000AID1061066
Carbonic anhydrase Nakaseomyces glabratus CBS 138Ki0.11800.00701.21749.1700AID744415
Carbonic anhydrase 13Homo sapiens (human)IC50 (µMol)0.02000.02000.86802.0000AID50185
Carbonic anhydrase 13Homo sapiens (human)Ki0.19050.00031.23099.8000AID1799673; AID603071
Carbonic anhydrase 4Bos taurus (cattle)IC50 (µMol)0.03600.02100.20600.6200AID48112; AID48114
Carbonic anhydrase 4Bos taurus (cattle)Ki0.15040.00300.59349.6500AID1796755; AID1797276; AID1797528; AID1799673; AID238597; AID258731; AID48119; AID48120; AID48121; AID48122; AID48124; AID48126; AID48130; AID48132; AID48280; AID48282; AID48286; AID48287; AID48288; AID48292
Carbonic anhydrase 15Mus musculus (house mouse)Ki0.06500.00091.884610.0000AID1798769; AID369275
Carbonic anhydrase 13Mus musculus (house mouse)Ki10.33240.00021.39749.9000AID1796980; AID1798598; AID238301; AID272528; AID311033; AID327768; AID367618; AID417835; AID48310
Carbonic anhydrase 14Homo sapiens (human)IC50 (µMol)0.02000.02000.53292.0000AID50185
Carbonic anhydrase 14Homo sapiens (human)Ki8.99860.00021.50999.9000AID1796980; AID1798598; AID239703; AID272529; AID293194; AID311034; AID327769; AID367619; AID417836; AID486936; AID614109
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)IC50 (µMol)0.02000.02000.86802.0000AID50185
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki8.63060.00001.34129.9700AID1796582; AID1796980; AID1798598; AID239287; AID256965; AID272524; AID311028; AID327763; AID367613; AID417830; AID578224
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
corticotropin-releasing hormone receptor 2Homo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
corticotropin releasing factor-binding proteinHomo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase Brucella suis 1330Kinact0.05400.01700.86285.8700AID459696
Carbonic anhydrase 12Homo sapiens (human)Kinact0.31220.00300.66749.6000AID1183268; AID299547; AID300757; AID316069; AID320314; AID328983; AID352790; AID386502; AID408472; AID411536
Carbonic anhydrase 1Homo sapiens (human)Kinact0.16230.01000.93878.6000AID1183265; AID293811; AID299242; AID299538; AID300754; AID316060; AID320305; AID328974; AID352787; AID386500; AID408469; AID411527
Carbonic anhydrase 2Homo sapiens (human)Kinact1.08980.00300.794610.0000AID1183266; AID293812; AID299243; AID299539; AID300755; AID316061; AID320306; AID328975; AID352788; AID386499; AID408470; AID411528
Carbonic anhydrase 3Homo sapiens (human)Kinact710.00003.30006.16578.0000AID316062
Carbonic anhydrase 4Homo sapiens (human)Kinact6.20000.07402.39348.5900AID299541; AID316063; AID320308; AID328977; AID411530
Carbonic anhydrase 6Homo sapiens (human)Kinact0.01000.00090.72615.3000AID299544; AID316066; AID320311; AID328980; AID411533
Dipeptidyl peptidase 4Homo sapiens (human)Kinact0.01400.00800.01740.0380AID386499
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Kinact0.06500.02000.85809.4000AID299542; AID316064; AID320309; AID328978; AID411531
Carbonic anhydrase 7Homo sapiens (human)Kinact0.00210.00020.28525.7300AID299545; AID316067; AID320312; AID328981; AID411534
Carbonic anhydrase 9Homo sapiens (human)Kinact2.27480.00500.31976.6700AID1183267; AID293813; AID299546; AID300756; AID316068; AID320313; AID328982; AID352789; AID386501; AID408471; AID411535
Carbonic anhydrase 13Mus musculus (house mouse)Kinact0.01900.01300.56698.2300AID299548; AID316070; AID320315; AID328984; AID411537
Carbonic anhydrase 14Homo sapiens (human)Kinact0.04300.00021.44958.5900AID299549; AID316071; AID320316; AID328985; AID411538
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Kinact0.06200.00900.92319.0400AID299543; AID316065; AID320310; AID328979; AID411532
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (322)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of phospholipase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
neural tube closureTyrosine-protein kinase ABL1Homo sapiens (human)
B-1 B cell homeostasisTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
B cell proliferation involved in immune responseTyrosine-protein kinase ABL1Homo sapiens (human)
transitional one stage B cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
mismatch repairTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of DNA-templated transcriptionTyrosine-protein kinase ABL1Homo sapiens (human)
autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
DNA damage responseTyrosine-protein kinase ABL1Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
associative learningTyrosine-protein kinase ABL1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
post-embryonic developmentTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
cerebellum morphogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
microspike assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of endocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
neuron differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of axon extensionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of microtubule polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of Cdc42 protein signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of interleukin-2 productionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of osteoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
response to endoplasmic reticulum stressTyrosine-protein kinase ABL1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein modification processTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
signal transduction in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of vasoconstrictionTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase ABL1Homo sapiens (human)
alpha-beta T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of fibroblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
spleen developmentTyrosine-protein kinase ABL1Homo sapiens (human)
thymus developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
activated T cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
neuromuscular process controlling balanceTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of oxidoreductase activityTyrosine-protein kinase ABL1Homo sapiens (human)
neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
myoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of stress fiber assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
establishment of localization in cellTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrial depolarizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of focal adhesion assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cardiac muscle cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
neuroepithelial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase ABL1Homo sapiens (human)
ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
DNA conformation changeTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
response to epinephrineTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of protein serine/threonine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of dendrite developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of long-term synaptic potentiationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of hematopoietic stem cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of extracellular matrix organizationTyrosine-protein kinase ABL1Homo sapiens (human)
podocyte apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to dopamineTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of establishment of T cell polarityTyrosine-protein kinase ABL1Homo sapiens (human)
DN4 thymocyte differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein localization to cytoplasmic microtubule plus-endTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of microtubule bindingTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of modification of synaptic structureTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of blood vessel branchingTyrosine-protein kinase ABL1Homo sapiens (human)
activation of protein kinase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of Wnt signaling pathway, planar cell polarity pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell motilityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of endothelial cell apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of T cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
10-formyltetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to xenobiotic stimulusDihydrofolate reductaseEscherichia coli K-12
folic acid biosynthetic processDihydrofolate reductaseEscherichia coli K-12
one-carbon metabolic processDihydrofolate reductaseEscherichia coli K-12
response to methotrexateDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to antibioticDihydrofolate reductaseEscherichia coli K-12
dihydrofolate metabolic processDihydrofolate reductaseEscherichia coli K-12
folic acid metabolic processDihydrofolate reductaseEscherichia coli K-12
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 13Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (116)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
supercoiled DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
magnesium ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
four-way junction DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
bubble DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ABL1Homo sapiens (human)
DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
transcription coactivator activityTyrosine-protein kinase ABL1Homo sapiens (human)
actin monomer bindingTyrosine-protein kinase ABL1Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase C bindingTyrosine-protein kinase ABL1Homo sapiens (human)
protein bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ATP bindingTyrosine-protein kinase ABL1Homo sapiens (human)
kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
SH3 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
syntaxin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
manganese ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
SH2 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
mitogen-activated protein kinase bindingTyrosine-protein kinase ABL1Homo sapiens (human)
proline-rich region bindingTyrosine-protein kinase ABL1Homo sapiens (human)
delta-catenin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
sequence-specific double-stranded DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
endopeptidase activityCathepsin BBos taurus (cattle)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseEscherichia coli K-12
protein bindingDihydrofolate reductaseEscherichia coli K-12
folic acid bindingDihydrofolate reductaseEscherichia coli K-12
oxidoreductase activityDihydrofolate reductaseEscherichia coli K-12
NADP bindingDihydrofolate reductaseEscherichia coli K-12
methotrexate bindingDihydrofolate reductaseEscherichia coli K-12
dihydrofolic acid bindingDihydrofolate reductaseEscherichia coli K-12
NADP+ bindingDihydrofolate reductaseEscherichia coli K-12
NADPH bindingDihydrofolate reductaseEscherichia coli K-12
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 13Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 13Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 13Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Bos taurus (cattle)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (71)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
ruffleTyrosine-protein kinase ABL1Homo sapiens (human)
nucleusTyrosine-protein kinase ABL1Homo sapiens (human)
nucleoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
nucleolusTyrosine-protein kinase ABL1Homo sapiens (human)
cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrionTyrosine-protein kinase ABL1Homo sapiens (human)
cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeletonTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear bodyTyrosine-protein kinase ABL1Homo sapiens (human)
dendriteTyrosine-protein kinase ABL1Homo sapiens (human)
growth coneTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear membraneTyrosine-protein kinase ABL1Homo sapiens (human)
neuronal cell bodyTyrosine-protein kinase ABL1Homo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
postsynapseTyrosine-protein kinase ABL1Homo sapiens (human)
protein-containing complexTyrosine-protein kinase ABL1Homo sapiens (human)
plasma membraneTyrosine-protein kinase ABL1Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
lysosomeCathepsin BBos taurus (cattle)
apical plasma membraneCathepsin BBos taurus (cattle)
melanosomeCathepsin BBos taurus (cattle)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
cytosolDihydrofolate reductaseEscherichia coli K-12
cytosolDihydrofolate reductaseEscherichia coli K-12
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
myelin sheathCarbonic anhydrase 13Homo sapiens (human)
intracellular membrane-bounded organelleCarbonic anhydrase 13Homo sapiens (human)
cytoplasmCarbonic anhydrase 13Homo sapiens (human)
cytosolCarbonic anhydrase 13Homo sapiens (human)
side of membraneCarbonic anhydrase 4Bos taurus (cattle)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (755)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1067230Inhibition of human cytosolic carbonic anhydrase 1 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID367611Inhibition of human recombinant full length CA4 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367611Inhibition of human recombinant full length CA4 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID238438Inhibition constant against human carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID1204094Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-1 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-122015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID25801The compound was evaluated for in Vitro corneal permeability when no epithelium1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route.
AID317582Selectivity for human CA9 over human CA12008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID764719Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.
AID47748Inhibitory activity of compound against human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.
AID47900Inhibition constant evaluated for the inhibition of human CA II (Carbonic anhydrase II)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID50354Inhibitory activity against human recombinant carbonic anhydrase I (CA1)2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
AID1142834Inhibition of human carbonic anhydrase-2 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID316065Inhibition of human recombinant full length carbonic hydrase 5B by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID239102Inhibitory constant against catalytic domain of human carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID411535Inhibition of human recombinant CA9 catalytic domain by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411535Inhibition of human recombinant CA9 catalytic domain by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328981Inhibition of human full length carbonic anhydrase 72008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID272529Inhibition of human cloned CA14 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID50380Inhibitory activity against human carbonic anhydrase I.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates.
AID1061069Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID1278410Inhibition of Porphyromonas gingivalis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1195370Inhibition of human carbonic anhydrase 2 pre-incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID50356Inhibitory activity against human cloned isoenzyme carbonic anhydrase I (hCA I), by esterase method.2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives.
AID47901Inhibitory activity against Human carbonic anhydrase II2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID764717Inhibition of human cytosolic carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.
AID50364Inhibition of human carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits.
AID167480Evaluated for effect on intraocular pressure(IOP) in rabbit after 1 hour1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.
AID17874Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.
AID48299Inhibition constant determined against catalytic domain of human cloned carbonic anhydrase IX2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID386502Inhibition of human cloned CA12 catalytic domain by stopped-flow CO2 hydration method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID47904Inhibitory activity against human cloned isoenzyme carbonic anhydrase II (hCA II), by esterase method.2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives.
AID1190065Inhibition of Plasmodium falciparum Eta-carbonic anhydrase pre-incubated for 15 mins before CO2 substrate addition by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID369271Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID316071Inhibition of human recombinant full length carbonic hydrase 14 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID237410Compound level in Red Blood Cells at 30 min, after exposure of 10 mL of Blood to compound solution by electronic spectroscopic method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID417826Inhibition of human recombinant full length CA2 expressed in Escherichia coli BL21 (DE3) by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID48124Inhibitory activity against carbonic anhydrase isolated from bovine lung microsome (bCA IV)2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV.
AID47710Inhibition of human recombinant carbonic anhydrase I (CA1)2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID770583Inhibition of human membrane bound carbonic anhydrase 9 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID321163Selectivity for human CA12 over human CA22008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID1262266Inhibition of weddell seal alphaCA incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID436563Inhibition of human recombinant CA1 by stopped-flow CO2 assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID254246Inhibitory activity against catalytic domain of human cloned Carbonic anhydrase IX by the CO2 hydration method2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID239284Inhibitory activity against catalytic domain of human carbonic anhydrase XII2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID238957Inhibitory activity against human carbonic anhydrase I at 0.09 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID408471Inhibition of human cloned CA9 catalytic domain by stopped flow CO2 hydration assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID287698Inhibition of human recombinant carbonic anhydrase 1 by CO2 hydration method2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
AID427122Inhibition of Candida albicans recombinant Nce103 by stopped-flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1154447Inhibition of human cloned transmembrane tumor-associated catalytic domain of carbonic anhydrase 9 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID118608Anticonvulsant activity in mice by MES test at 0.5 h following intraperitoneal injection of 30 mg/kg dose.2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
AID725955Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID261581Inhibition of Helicobacter pylori recombinant carbonic anhydrase by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID48301Inhibitory activity against human carbonic anhydrase IX2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID271712Inhibition of human cloned CA9 catalytic domain by CO2 hydration method2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID4773250% inhibition of human carbonic anhydrase II assayed by CO2 hydration catalyzed by human erythrocytes1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity.
AID725956Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID1204093Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-2 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-92015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID27788Calculated partition coefficient (clogP) (MlogP)2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.
AID48288Inhibition of bovine carbonic anhydrase IV (CA4) from bovine lung microsomes2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID47902Inhibitory activity against human recombinant carbonic anhydrase II (CA2)2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
AID275806Inhibition of full length human recombinant CA VI2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID414956Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration method2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID411533Inhibition of human recombinant CA6 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411533Inhibition of human recombinant CA6 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID239223Inhibitory potency against human cloned Carbonic anhydrase I expressed in Escherichia coli strain BL212005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX.
AID320315Inhibition of mouse recombinant full length carbonic hydrase 13 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID93579Level in red blood cells after incubation of human erythrocytes for 30 min, was determined by EI method2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID238830Inhibitory activity against human carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID271713Selectivity for human CA9 over CA12006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID238256Ki value against human carbonic anhydrase VII2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID328985Inhibition of human full length carbonic anhydrase 142008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID427124Inhibition of Helicobacter pylori beta-carbonic anhydrase by stopped-flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID411527Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411527Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID321162Selectivity for human CA12 over human CA12008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID238597Inhibitory activity against bovine carbonic anhydrase IV (bCAIV)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID408473Selectivity for human cloned CA9 over human recombinant CA12008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID552128Inhibition of human recombinant CA2 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID166955In vitro transcorneal accession rate in rabbit corneal intact epithelium2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID50345Inhibitory activity against human carbonic anhydrase I was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID261582Selectivity ratio for human carbonic anhydrase 2 over Helicobacter pylori carbonic anhydrase2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID239287Mean inhibitory constant towards human carbonic anhydrase V determined by spectrophotometric dansylamide binding assay2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies.
AID272526Inhibition of catalytic domain of human cloned CA9 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1275910Inhibition of Vibrio cholerae beta-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID367619Inhibition of human recombinant full length CA14 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367619Inhibition of human recombinant full length CA14 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID367615Inhibition of human recombinant full length CA7 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367615Inhibition of human recombinant full length CA7 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID233702Selectivity ratio, inhibition (Ki) of human carbonic anhydrase IX compared to human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID238437Inhibition constant against human carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID411534Inhibition of human recombinant CA7 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411534Inhibition of human recombinant CA7 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID47938Inhibitory activity against human recombinant carbonic anhydrase II2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID21971Tested for solubility in pH 7.4 buffer, at 25 Degree C2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID411538Inhibition of human recombinant CA14 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411538Inhibition of human recombinant CA14 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1195371Inhibition of Anopheles gambiae carbonic anhydrase pre-incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID48121Inhibitory activity against bovine carbonic anhydrase IV (CA4), obtained from bovine lung microsomes2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.
AID770585Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID238852Mean inhibitory constant towards human carbonic anhydrase II determined by stopped-flow method2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies.
AID1278412Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID281084Inhibition of catalytic domain of human recombinant isozyme CA9 by CO2 hydration method2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID47750Inhibitory activity against carbonic anhydrase II2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.
AID734185Inhibition of recombinant human carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay2013European journal of medicinal chemistry, Apr, Volume: 62Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship.
AID47905Inhibitory effect on human Carbonic anhydrase II2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
AID1262264Inhibition of human CA2 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID1183265Inhibition of human cloned CA1 pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID299549Inhibition of human CA142007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID195091Inhibitor level was measured in red blood cells at 30 min after exposure of 10 mL of blood to solutions by enzymatic method (EI)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes.
AID275809Inhibition of catalytic domain of human recombinant CA IX2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID1453413Inhibition of human carbonic anhydrase-2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID300869Inhibition of human cloned catalytic domain CA9 by CO2 hydration method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID764718Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.
AID166954In vitro transcorneal accession rate in rabbit corneal denuded epithelium2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID311034Inhibition of human carbonic anhydrase 142007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID238309Inhibitory activity against human Carbonic anhydrase I2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.
AID1379904Inhibition of recombinant human full-length carbonic anhydrase 2 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors.
AID47942Inhibitory activity against human carbonic anhydrase II2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide.
AID48120In vitro inhibitory activity against bovine carbonic anhydrase IV (CAIV)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.
AID644379Inhibition of GST-tagged astrosclera willeyana Astrosclerin-3 expressed in Escherichia coli after 15 mins preincubation by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID271039Inhibition of human cloned CA9 catalytic domain by CO2 hydration assay2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID237405Compound level in Red Blood Cells at 30 min, after exposure of 10 mL of Blood to compound solution by HPLC method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID293194Inhibition of human recombinant CA14 by CO2 hydration assay2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides.
AID328980Inhibition of human full length carbonic anhydrase 62008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID48303Inhibitory activity against human carbonic anhydrase IX (hCA IX) by using CO2 hydrase assay method2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID448553Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase Rv1284 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides.
AID1154448Inhibition of human cloned transmembrane tumor-associated catalytic domain of carbonic anhydrase 12 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID1061169Inhibition of recombinant Methanosarcina thermophila gamma-CA CAM by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID239422Inhibitory potency against catalytic domain of human Carbonic anhydrase IX expressed in Escherichia coli strain BL212005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX.
AID552127Inhibition of human recombinant CA1 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID587132Inhibition of Leptonychotes weddellii alpha-carbonic anhydrase after 15 mins by CO2 hydrase assay at pH 7.52011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID578223Inhibition of human recombinant CA5A mitochondrial isoform by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
(R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases.
AID48119Inhibition of bovine membrane bound isozyme carbonic anhydrase IV isolated from microsomes at 20 degree C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID411531Inhibition of human recombinant CA5A by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411531Inhibition of human recombinant CA5A by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID349605Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID166790Corneal penetration rate constant (k) for excised intact cornea of albino rabbit1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide.
AID238774Binding affinity towards human cloned carbonic anhydrase IX2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID321156Inhibition of human recombinant CA1 by CO2 hydration stopped flow assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID1347712Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydration assay
AID48092Inhibition of human carbonic anhydrase II2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors.
AID587131Inhibition of human carbonic anhydrase 2 after 15 mins by CO2 hydrase assay at pH 7.52011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID1723531Antibacterial activity against Enterococcus faecium ATCC 700221 by CLSI protocol based assay
AID48130Compound was evaluated for inhibition against bovine carbonic anhydrase IV2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX.
AID577530Inhibition of Brucella suis carbonic anhydrase II by spectrophotometry at pH 8.32011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID238300Ki value against human carbonic anhydrase II (hCA II)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID320313Inhibition of human catalytic domain carbonic hydrase 9 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID316069Inhibition of human catalytic domain carbonic hydrase 12 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID408476Selectivity for human cloned CA12 over human recombinant CA22008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID603069Inhibition of human recombinant cytosolic carbonic anhydrase 3 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID243090Ratio of inhibition of carbonic anhydrase IV in human to that of carbonic anhydrase IV in bovine2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID281083Inhibition of human recombinant isozyme CA2 by CO2 hydration method2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID272528Inhibition of murine CA13 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID386501Inhibition of human cloned CA9 catalytic domain by stopped-flow CO2 hydration method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID1188134Inhibition of human recombinant Carbonic anhydrase 1 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID321161Selectivity for human CA9 over human CA22008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID1434428Inhibition of human carbonic anhydrase 2 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID327761Inhibition of human full length carbonic anhydrase 4 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID327766Inhibition of human catalytic domain carbonic anhydrase 9 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID244228Ratio of inhibitory potency against carbonic anhydrase II to that of inhibitory potency against carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX.
AID414955Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration method2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID48287Inhibitory activity against carbonic anhydrase IV from bovine lung microsomes2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID411536Inhibition of human recombinant CA12 catalytic domain by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411536Inhibition of human recombinant CA12 catalytic domain by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID239145Inhibitory activity against alpha carbonic anhydrase (Co-Cam) from Methanosarcina thermophila2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID300867Inhibition of human cloned CA1 by CO2 hydration method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID352788Inhibition of human recombinant CA2 by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII.
AID229677Selectivity ratio towards hCA IX as compared to hCA II2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates.
AID587130Inhibition of human carbonic anhydrase 1 after 15 mins by CO2 hydrase assay at pH 7.52011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Purification and inhibition studies with anions and sulfonamides of an α-carbonic anhydrase from the Antarctic seal Leptonychotes weddellii.
AID417837Inhibition of Caenorhabditis elegans CAH-4b by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID47899In vitro inhibitory activity against human carbonic anhydrase II (hCAII)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.
AID299552Inhibition of Methanosarcina thermophila gamma CA2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID258733Inhibitory activity against cloned human CA122006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID328984Inhibition of mouse full length carbonic anhydrase 132008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID281082Inhibition of human recombinant isozyme CA1 by CO2 hydration method2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID299545Inhibition of human CA72007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1379902Inhibition of recombinant human full-length carbonic anhydrase 1 preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors.
AID743513Inhibition of Helicobacter pylori recombinant alpha carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID417833Inhibition of human recombinant CA9 catalytic domain by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID577526Inhibition of human carbonic anhydrase I by spectrophotometry at pH 7.52011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID263638Inhibition of Helicobacter pylori recombinant CA2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID367613Inhibition of human recombinant full length CA5B by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367613Inhibition of human recombinant full length CA5B by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID367610Inhibition of human recombinant full length CA3 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367610Inhibition of human recombinant full length CA3 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID614109Inhibition of human cloned full length carbonic anhydrase 14 preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID195090Inhibitor level was measured in red blood cells at 30 min after exposure of 10 mL of blood to solutions by electronic spectroscopic (ES) method2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes.
AID195087168 Inhibitor level was measured in red blood cells at 60 min after exposure of 10 mL of blood to solutions by HPLC method2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes.
AID408469Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID614107Inhibition of human cloned carbonic anhydrase 9 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID711212Inhibition of recombinant Vibrio cholerae carbonic anhydrase expressed in Escherichia coli (DE3) preincubated for 15 mins by stopped-flow CO2 hydrase assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
DNA cloning, characterization, and inhibition studies of an α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID23571The solubility at pH 7.40 and 25 degree Centigrade was evaluated.1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route.
AID238788Inhibitory activity against human carbonic anhydrase IX expressed in Escherichia coli BL212004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID320308Inhibition of human recombinant full length carbonic hydrase 4 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID417832Inhibition of human recombinant full length CA7 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID316070Inhibition of mouse recombinant full length carbonic hydrase 13 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID369272Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID93583Level in red blood cells after incubation of human erythrocytes for 60 min, was determined by ES method2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID417834Inhibition of human recombinant CA12 catalytic domain by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID1190064Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID386499Inhibition of human cloned CA2 by stopped-flow CO2 hydration method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID770584Inhibition of human cytosolic carbonic anhydrase 7 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID271037Inhibition of human cloned CA1 by CO2 hydration assay2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID118610Anticonvulsant activity in mice by MES test at 3.0 hr following intraperitoneal injection of 10 mg/kg dose.2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
AID369273Inhibition of human full length recombinant carbonic anhydrase 6 by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID195093Inhibitor level was measured in red blood cells at 60 min after exposure of 10 mL of blood to solutions by electronic spectroscopic (ES) method2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes.
AID321159Inhibition of human recombinant CA12 by CO2 hydration stopped flow assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID321158Inhibition of human recombinant CA9 by CO2 hydration stopped flow assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID50344Inhibitory activity of compound against human carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.
AID311028Inhibition of human carbonic anhydrase 5B2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID238259Ratio against Carbonic anhydrase II to Carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID349606Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1262263Inhibition of human CA1 incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID238211Inhibitory constant against human Carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID271174Inhibition of human recombinant carbonic anhydrase 9 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID327760Inhibition of human full length carbonic anhydrase 3 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID300870Selectivity ratio of Ki for human cloned CA1 to Ki for human cloned catalytic domain CA92007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID436564Inhibition of human recombinant CA2 by stopped-flow CO2 assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID512001Inhibition of human cloned CA1 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512001Inhibition of human cloned CA1 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID243098Ratio of inhibitory activity of human cytosolic carbonic anhydrase II to tumor associated carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID48088Inhibitory activity against human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID244307Percent of mice (n=8) protected against seizures induced by a maximal electroshock (50mA,0.2s) after 30 mg/kg compound was injected intraperitoneally2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties.
AID603067Inhibition of human recombinant cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID1067225Selectivity ratio of Ki for human transmembrane carbonic anhydrase 2 to Ki for human cytosolic carbonic anhydrase 122014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID293193Inhibition of human recombinant CA12 by CO2 hydration assay2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides.
AID50379Inhibitory activity against human carbonic anhydrase I (hCA I) by using esterase assay method2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
AID448552Inhibition of human cloned full length carbonic anhydrase 2 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides.
AID603070Inhibition of human recombinant cytosolic carbonic anhydrase 7 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID48122Inhibitory activity against bovine carbonic anhydrase IV2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID512003Inhibition of human cloned catalytic domain of CA9 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512003Inhibition of human cloned catalytic domain of CA9 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID316062Inhibition of human recombinant full length carbonic hydrase 3 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID50377Inhibitory activity against human carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID578221Inhibition of human recombinant CA1 cytosolic isoform by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
(R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases.
AID1140817Inhibition of human carbonic anhydrase 1-catalyzed CO2 hydration preincubated for 10 mins by stopped-flow assay2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Carbonic anhydrase inhibitors. Inhibition of human cytosolic isoforms I and II with (reduced) Schiff's bases incorporating sulfonamide, carboxylate and carboxymethyl moieties.
AID238770Inhibitory activity against human carbonic anhydrase I expressed in Escherichia coli BL212004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID20165In vitro susceptibility to nucleophilic attack by reduced glutathione at 37 degree C and at pH 7.41989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide.
AID238220Inhibitory constant against human Carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID427125Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase method2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID386506Selectivity for human CA12 over human CA22008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID327762Inhibition of human full length carbonic anhydrase 5A by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID237404Compound level in Red Blood Cells at 48 h, after exposure of 10 mL of Blood to compound solution by HPLC method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID131557Protective dose against maximal electroshock in mice after peroral administration1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides.
AID293812Inhibition of human recombinant CA2 by stopped flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID726232Inhibition of Trypanosoma cruzi CL Brener recombinant alpha-carbonic anhydrase expressed in insect Sf9 cell Baculovirus system by stopped flow CO2 hydration assay2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease.
AID48304Inhibitory activity against human carbonic anhydrase IX.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates.
AID272522Inhibition of human cloned CA4 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID272525Inhibition of human cloned CA7 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1240217Inhibition of human recombinant carbonic anhydrase-2 by stopped flow CO2 hydrase assay method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1287520Inhibition of recombinant Enterobacter sp. B13 beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID1062686Inhibition of human CA2 cytosolic isoform after 15 mins by stopped-flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID50357Inhibitory effect on human carbonic anhydrase I2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
AID256964Inhibitory activity against human recombinant mitochondrial isozyme CA VA2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID300754Inhibition of human recombinant CA1 by CO2 hydration stopped flow assay2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.
AID258731Inhibitory activity against CA4 isolated from bovine lung microsomes2006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID48126Inhibitory effect on bovine Carbonic anhydrase IV2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
AID258732Inhibitory activity against cloned human CA92006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID1194028Inhibition of recombinant Nostoc commune gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID299539Inhibition of human CA22007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID238255Ki value against human carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID222126Inhibition of cloned isozyme, human carbonic anhydrase II2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties.
AID237409Compound level in Red Blood Cells at 48 h, after Exposure of 10 mL of Blood to Compound solution by electronic spectroscopic method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID293813Inhibition of human recombinant CA9 by stopped flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID1188138Inhibition of Porphyromonas gingivalis Gamma-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID275808Inhibition of human recombinant cytosolic isozyme CA II by stopped-flow CO2 hydrase method2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID612732Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 2 at pH 8.3 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID411537Inhibition of mouse recombinant CA13 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411537Inhibition of mouse recombinant CA13 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID48294Inhibitory activity against human carbonic anhydrase IX was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
AID47898Inhibition of human cytosolic isozyme Carbonic anhydrase II at 20 degree C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID243011Selectivity ratio against human carbonic anhydrases II and XII2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID244127Ratio of Ki for human carbonic anhydrases II and IX2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID48282Inhibitory activity against bovine carbonic anhydrase IV from lung microsomes2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID328977Inhibition of human full length carbonic anhydrase 42008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1204095Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-2 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-122015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID254240Inhibitory activity against human cloned Carbonic anhydrase I by the CO2 hydration method2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID1628038Inhibition of recombinant Plasmodium falciparum eta-carbonic anhydrase (181 to 538 residues) expressed in Escherichia coli artic express (DE3) preincubated for 15 mins by stop flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID238575Inhibitory activity against human carbonic anhydrase IV (hCAIV)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID327768Inhibition of mouse full length carbonic anhydrase 13 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID331500Inhibition of human cloned carbonic anhydrase 9 by CO2 hydration stopped-flow assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1347713Inhibition of human carbonic anhydrase 9 by stopped-flow CO2 hydration assay
AID320311Inhibition of human recombinant full length carbonic hydrase 6 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID644380Inhibition of human recombinant carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID317583Selectivity for human CA9 over human CA22008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID512004Inhibition of human cloned catalytic domain of CA12 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512004Inhibition of human cloned catalytic domain of CA12 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1183267Inhibition of human cloned CA9 catalytic domain pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID238635Inhibitory activity against cytosolic human carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID1379906Inhibition of recombinant human carbonic anhydrase 12 catalytic domain preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors.
AID47736In vitro inhibition of human Carbonic Anhydrase II1989Journal of medicinal chemistry, Nov, Volume: 32, Issue:11
Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide.
AID47936Inhibition of human carbonic anhydrase II2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID166653Tested in vitro for transcorneal accession rates (corneal permeability) against cornea with no epithelium2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID327764Inhibition of human full length carbonic anhydrase 6 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID272521Inhibition of human cloned CA2 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1188137Inhibition of Porphyromonas gingivalis Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID328982Inhibition of human catalytic domain carbonic anhydrase 92008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1434429Inhibition of Burkholderia pseudomallei Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID238620Inhibitory activity against cytosolic human carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID48132Inhibition constant against bovine Carbonic anhydrase IV, isolated from lung microsomes2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID1067226Selectivity ratio of Ki for human transmembrane carbonic anhydrase 2 to Ki for human cytosolic carbonic anhydrase 92014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID411532Inhibition of human recombinant CA5B by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411532Inhibition of human recombinant CA5B by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1188136Inhibition of Helicobacter pylori Beta-carbonic anhydrase compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID743514Inhibition of human recombinant carbonic anhydrase 2 preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID328983Inhibition of human catalytic domain carbonic anhydrase 122008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID316068Inhibition of human catalytic domain carbonic hydrase 9 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID50352Inhibition constant evaluated for the inhibition of human CA I (Carbonic anhydrase I)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID367618Inhibition of mouse recombinant full length CA13 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367618Inhibition of mouse recombinant full length CA13 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID239703Inhibitory constant against human carbonic anhydrase XIV in CO2 hydrase assay2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID299243Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID238772Binding affinity towards human cloned carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID299538Inhibition of human CA12007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID327767Inhibition of human catalytic domain carbonic anhydrase 12 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID50366Inhibition constant determined against human cloned carbonic anhydrase I2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID1268965Inhibition of recombinant Thiomicrospira crunogena XCL-2 carbonic anhydrase by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID48286Inhibitory activity against Carbonic anhydrase IV isolated from bovine lung2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide.
AID1278413Inhibition of recombinant Colwellia psychrerythraea gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID734183Inhibition of recombinant human carbonic anhydrase 9 after 15 mins by stopped flow CO2 hydration assay2013European journal of medicinal chemistry, Apr, Volume: 62Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship.
AID311026Inhibition of human carbonic anhydrase 42007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID352789Inhibition of human CA9 catalytic domain by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII.
AID669117Inhibition of Candida albicans CaNce103 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID48280Inhibitory activity against bovine carbonic anhydrase isozyme IV isolated from bovine lung microsomes, by esterase assay method.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID349608Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 3 expressed in Escherichia coli BL21 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID47929Inhibition of human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits.
AID327758Inhibition of human full length carbonic anhydrase 1 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID238276Ki value against human carbonic anhydrase I (hCA I)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID238301Ki value against murine carbonic anhydrase XIII2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID23922Lipophilicity of the compound2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
AID263636Inhibition of human recombinant CA12006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID367614Inhibition of human recombinant full length CA6 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367614Inhibition of human recombinant full length CA6 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID23539Solubility (in uM) in pH 7.40 at 25 degree C2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID328975Inhibition of human full length carbonic anhydrase 22008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID26085pKa of the compound was determined1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1190063Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
AID238409Inhibition constant against human carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID327763Inhibition of human full length carbonic anhydrase 5B by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID118606Anticonvulsant activity in mice by MES test at 0.5 hr following intraperitoneal injection of 10 mg/kg dose.2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
AID320310Inhibition of human recombinant full length carbonic hydrase 5B by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID50362Compound was evaluated for inhibition against human carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX.
AID770586Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID448554Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase Rv3273 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides.
AID327765Inhibition of human full length carbonic anhydrase 7 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID1142838Inhibition of Helicobacter pylori carbonic anhydrase by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID238760Binding affinity towards human cloned carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID614106Inhibition of human cloned carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID408472Inhibition of human cloned CA12 catalytic domain by stopped flow CO2 hydration assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID272524Inhibition of human cloned CA5B by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID50355Inhibitory activity against human cloned carbonic anhydrase I (hCA I)2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV.
AID237411Compound level in Red Blood Cells at 60 min, after exposure of 10 mL of Blood to compound solution by electronic spectroscopic method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311024Inhibition of human carbonic anhydrase 22007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID417831Inhibition of human recombinant full length CA6 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID1194025Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID48090Inhibitory activity against human carbonic anhydrase II (hCA II) by using esterase assay method2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
AID271172Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID26762Partition coefficient (logD) (chloroform/buffer)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route.
AID644381Inhibition of human recombinant carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.
AID612731Inhibition of Salmonella Typhimurium recombinant carbonic anhydrase 1 at pH 8.3 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID238247Ki value against human carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
AID552131Inhibition of Stylophora pistillata carbonic anhydrase 2 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID48114Inhibitory activity against bovine carbonic anhydrase IV was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
AID552130Inhibition of Stylophora pistillata carbonic anhydrase by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID281085Selectivity ratio of human CA9 over human CA12007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID47940Inhibitory activity against human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID48112Inhibitory activity of compound against bovine carbonic anhydrase IV2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.
AID48296Inhibitory activity against human tumor-associated transmembrane carbonic anhydrase IX.2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides.
AID317580Inhibition of human cloned CA2 by CO2 hydration method2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID1195369Inhibition of human carbonic anhydrase 1 pre-incubated for 15 mins by stopped-flow CO2 hydration assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
The β-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
AID770581Selectivity ratio of Ki for human carbonic anhydrase 2 to Ki for human carbonic anhydrase 92013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID48297Compound was evaluated for inhibition against human carbonic anhydrase IX2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX.
AID1142836Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-1 assessed as CO2 hydrase activity by stopped-flow assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID612726Inhibition of human recombinant carbonic anhydrase 2 at pH 7.5 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID50351In vitro inhibitory activity against human carbonic anhydrase I (hCAI)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.
AID669119Inhibition of GST-tagged Malassezia globosa ATCC 96807/CBS 7966 MG-CA expressed in Escherichia coli BL21(DE3) cells preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID552129Inhibition of human recombinant CA6 by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.
AID1194026Inhibition of recombinant Methanosarcina thermophila gamma-carbonic anhydrase by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID238227Inhibitory constant against human Carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID512002Inhibition of human cloned CA2 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID512002Inhibition of human cloned CA2 after 15 mins by stopped-flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID300868Inhibition of human cloned CA2 by CO2 hydration method2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID50353Inhibitory activity against Human carbonic anhydrase I2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.
AID1278411Inhibition of Nostoc commune gamma carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID272523Inhibition of human cloned CA5A by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID386505Selectivity for human CA12 over human CA12008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID263637Inhibition of human recombinant CA22006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID437749Inhibition of human recombinant CA2 by stopped-flow hydration assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID1142833Inhibition of human carbonic anhydrase-1 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1183266Inhibition of human cloned CA2 pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID744415Inhibition of recombinant full length Candida glabrata NCE103 expressed in Escherichia coli BL21 preincubated for 15 mins by stopped-flow CO2 hydrase assay2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides.
AID578222Inhibition of human recombinant CA2 cytosolic isoform by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
(R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases.
AID1240214Inhibition of Nostoc commune gamma carbonic anhydrase by CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1061068Inhibition of Leishmania donovani chagasi recombinant beta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID48292Inhibition constant evaluated for the inhibition of bovine CA IV (Carbonic anhydrase IV)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID222125Inhibition of cloned isozyme, human carbonic anhydrase I2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties.
AID239240Inhibitory potency against human cloned Carbonic anhydrase II expressed in Escherichia coli strain BL212005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX.
AID327759Inhibition of human full length carbonic anhydrase 2 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID486936Inhibition of human full length carbonic anhydrase 14 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486936Inhibition of human full length carbonic anhydrase 14 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1154445Inhibition of human cloned cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID238986Inhibitory activity against human carbonic anhydrase II at 0.01 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID48309Inhibition of murine mitochondrial isozyme Carbonic anhydrase V at 20 degrees C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID1379905Inhibition of recombinant human carbonic anhydrase 9 catalytic domain preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017ACS medicinal chemistry letters, Sep-14, Volume: 8, Issue:9
Exploring Heteroaryl-pyrazole Carboxylic Acids as Human Carbonic Anhydrase XII Inhibitors.
AID317581Inhibition of human CA9 catalytic domain by CO2 hydration method2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID427123Inhibition of Cryptococcus neoformans recombinant Can2 by stopped-flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID331501Selectivity ratio of Ki for human recombinant carbonic anhydrase 2 to Ki for human cloned carbonic anhydrase 92008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID271040Inhibition of human cloned CA12 catalytic domain by CO2 hydration assay2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID1204091Inhibition of recombinant human transmembrane, tumor-associated form of carbonic anhydrase-12 preincubated for 15 mins by stopped flow CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID47709Inhibition of human recombinant carbonic anhydrase I2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors.
AID93580Level in red blood cells after incubation of human erythrocytes for 30 min, was determined by ES method2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID258729Inhibitory activity against cloned human CA12006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID25621Evaluated for sulfonamide pKa, free acid water solubility1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.
AID417836Inhibition of human recombinant full length CA14 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID1154446Inhibition of human cloned cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
AID299544Inhibition of human CA62007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID320314Inhibition of human catalytic domain carbonic hydrase 12 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID733808Selectivity ratio of IC50 for recombinant human carbonic anhydrase 2 to IC50 for recombinant human carbonic anhydrase 92013European journal of medicinal chemistry, Apr, Volume: 62Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship.
AID331498Inhibition of human recombinant carbonic anhydrase 1 by CO2 hydration stopped-flow assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID411530Inhibition of human recombinant CA4 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411530Inhibition of human recombinant CA4 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID195089Inhibitor level was measured in red blood cells at 30 min after exposure of 10 mL of blood to solutions by HPLC method2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes.
AID320306Inhibition of human recombinant full length carbonic hydrase 2 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID299541Inhibition of human CA42007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID300757Inhibition of human CA12 catalytic domain by CO2 hydration stopped flow assay2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.
AID1287517Inhibition of human carbonic anhydrase 1 incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID414961Inhibition of Mycobacterium tuberculosis H37Rv recombinant beta-carbonic anhydrase 1 expressed in Escherichia coli BL21 by stopped flow CO2 hydration method2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID311030Inhibition of human carbonic anhydrase 72007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID1240215Inhibition of Pseudoalteromonas haloplanktis gamma carbonic anhydrase by CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID238223Inhibitory constant against human Carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID28907Partition coefficient (logD) (chloroform/buffer)2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID239048Inhibitory activity against membrane bound tumor associated human carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Feb-01, Volume: 15, Issue:3
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
AID47903Inhibitory activity against human cloned carbonic anhydrase II (hCA II)2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV.
AID349607Inhibition of Mycobacterium tuberculosis recombinant carbonic anhydrase 1 encoded by Rv1284 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID614108Inhibition of human cloned carbonic anhydrase 12 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID367609Inhibition of human recombinant full length CA2 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367609Inhibition of human recombinant full length CA2 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID300871Selectivity ratio of Ki for human cloned CA1 to Ki for human cloned catalytic domain CA92007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety.
AID577527Inhibition of human carbonic anhydrase II by spectrophotometry at pH 7.52011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID299542Inhibition of human CA5A2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID352790Inhibition of human CA12 catalytic domain by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII.
AID21085Evaluated for lipid solubility measured as partition coefficient at a pH 7.4 (CHCl3/buffer)1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.
AID48305Inhibitory concentration against catalytic domain of human cloned carbonic anhydrase IX.2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors.
AID25800The compound was evaluated for in Vitro corneal permeability at cornea intact1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route.
AID1268963Inhibition of recombinant human carbonic anhydrase-2 by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID238316Ki value against human carbonic anhydrase XII (hCA XII)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1434427Inhibition of recombinant human carbonic anhydrase 1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID408475Selectivity for human cloned CA12 over human recombinant CA12008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID311027Inhibition of human carbonic anhydrase 5A2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID238773Binding affinity towards human cloned carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties.
AID1061066Inhibition of Thalassiosira weissflogii delta carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID244399Selectivity ratio of Inhibitory constant against human carbonic anhydrase II to carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID47931Inhibition constant (Ki) against human cloned carbonic anhydrase II (CAH)2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID299543Inhibition of human CA5B2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID238761Binding affinity towards human cloned carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties.
AID316063Inhibition of human recombinant full length carbonic hydrase 4 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID320316Inhibition of human recombinant full length carbonic hydrase 14 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID1434430Inhibition of Vibrio cholerae Gamma-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 sec by Line-Weaver Burk plot analysis
AID486935Inhibition of human cloned carbonic anhydrase 12 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486935Inhibition of human cloned carbonic anhydrase 12 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1204106Inhibition of recombinant Streptococcus mutans UA159 beta-carbonic anhydrase expressed in Escherichia coli Arctic cells preincubated for 15 mins by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Sulfonamide inhibition study of the β-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
AID328974Inhibition of human full length carbonic anhydrase 12008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1628036Inhibition of full length human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stop flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID681388TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1.
AID1593068Inhibition of human CA 12 catalytic domain2019European journal of medicinal chemistry, Apr-15, Volume: 168Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID1268964Inhibition of recombinant Sulfurihydrogenibium yellowstonense YO3AOP1 carbonic anhydrase by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID271175Selectivity for human recombinant carbonic anhydrase 9 over carbonic anhydrase 22006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID367821Inhibition of human recombinant CA2 by stopped-flow CO2 hydrase assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID165492Reduction in maximum Intra ocular pressure in the rabbit model of ocular hypertension, when treated with a minimum effective oral dose of 5 mg/Kg1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity.
AID238768Inhibitory activity against Carbonic anhydrase II2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID239146Inhibitory activity against alpha carbonic anhydrase (Zn-Cam) from Methanosarcina thermophila2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID271711Inhibition of human cloned CA2 by CO2 hydration method2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID417829Inhibition of human recombinant full length CA5A by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID263639Selectivity for Helicobacter pylori recombinant CA over human recombinant CA22006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.
AID166654Tested in vitro for transcorneal accession rates (corneal permeability) against intact cornea2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID603068Inhibition of human recombinant cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID316060Inhibition of human recombinant full length carbonic hydrase 1 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID238753Inhibitory activity against Carbonic anhydrase I2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID50375Inhibitory activity against human carbonic anhydrase I2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered.
AID1062685Inhibition of human CA9 after 15 mins by stopped-flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID299547Inhibition of human CA122007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID299250Inhibition of Helicobacter pylori beta carbonic anhydrase by stopped-flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID486934Inhibition of human cloned carbonic anhydrase 9 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486934Inhibition of human cloned carbonic anhydrase 9 catalytic domain preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID1183268Inhibition of human cloned CA12 catalytic domain pre-incubated with enzyme for 15 mins by phenol red based CO2 hydration stopped-flow assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID317579Inhibition of human cloned CA1 by CO2 hydration method2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides.
AID293811Inhibition of human recombinant CA1 by stopped flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID238850Inhibitory activity against human carbonic anhydrase II2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
AID47749Inhibitory activity against human carbonic anhydrase II was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
AID238536Inhibitory activity against human carbonic anhydrase I (hCAI)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID1275913Inhibition of human Carbonic anhydrase1 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID669116Inhibition of Cryptococcus neoformans Can2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID272520Inhibition of human cloned CA1 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID300756Inhibition of human CA9 catalytic domain by CO2 hydration stopped flow assay2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.
AID48295Inhibition constant evaluated for the inhibition of human CA IX (Carbonic anhydrase IX)2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID327769Inhibition of human full length carbonic anhydrase 14 by stopped flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.
AID417825Inhibition of human recombinant full length CA1 expressed in Escherichia coli BL21 (DE3) by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID238787Inhibitory activity against human carbonic anhydrase II expressed in Escherichia coli BL212004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
AID367616Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367616Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID612725Inhibition of human recombinant carbonic anhydrase 1 at pH 7.5 by stopped flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID734182Selectivity ratio of IC50 for recombinant human carbonic anhydrase 1 to IC50 for recombinant human carbonic anhydrase 92013European journal of medicinal chemistry, Apr, Volume: 62Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship.
AID411528Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411528Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID417830Inhibition of human recombinant full length CA5B by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID411529Inhibition of human recombinant CA3 by stopped flow CO2 hydration assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411529Inhibition of human recombinant CA3 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1240216Inhibition of Methanosarcina thermophila recombinant gamma carbonic anhydrase by stopped flow CO2 hydrase assay method2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID19197Partition coefficient (logP)1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides.
AID48093Inhibition of human recombinant carbonic anhydrase II (CA2)2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID486932Inhibition of human cloned carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486932Inhibition of human cloned carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID328979Inhibition of human full length carbonic anhydrase 5B2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1062687Inhibition of human CA1 cytosolic isoform after 15 mins by stopped-flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID320305Inhibition of human recombinant full length carbonic hydrase 1 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID1204092Selectivity ratio Ki for recombinant human cytosolic form of carbonic anhydrase-1 to Ki for recombinant human transmembrane, tumor-associated form of carbonic anhydrase-92015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Synthesis of Schiff base derivatives of 4-(2-aminoethyl)-benzenesulfonamide with inhibitory activity against carbonic anhydrase isoforms I, II, IX and XII.
AID1061067Inhibition of Porphyromonas gingivalis recombinant gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the δ-carbonic anhydrase from the diatom Thalassiosira weissflogii.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1593066Inhibition of full length human CA 22019European journal of medicinal chemistry, Apr-15, Volume: 168Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID367612Inhibition of human recombinant full length CA5A by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367612Inhibition of human recombinant full length CA5A by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID311031Inhibition of human carbonic anhydrase 92007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID238224Inhibitory constant against human Carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID369275Inhibition of mouse recombinant carbonic anhydrase 15 by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1067229Inhibition of human cytosolic carbonic anhydrase 2 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID1268962Inhibition of recombinant human carbonic anhydrase-1 by stopped flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.
AID367617Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367617Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID778725Inhibition of recombinant Leishmania donovani chagasi beta-carbonic anhydrase expressed in baculovirus infected insect Sf9 cells incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis.
AID1287518Inhibition of human carbonic anhydrase 2 incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID261580Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID386500Inhibition of human cloned CA1 by stopped-flow CO2 hydration method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID367822Inhibition of Saccharomyces cerevisiae recombinant CA expressed in Escherichia coli by stopped-flow CO2 hydrase assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID50371Inhibitory activity against human cloned carbonic anhydrase isozyme I by esterase assay method.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID417827Inhibition of human recombinant full length CA3 expressed in Escherichia coli BL21 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID331499Inhibition of human recombinant carbonic anhydrase 2 by CO2 hydration stopped-flow assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
AID316064Inhibition of human recombinant full length carbonic hydrase 5A by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID48300Inhibitory activity against human cloned carbonic anhydrase isozyme IX, by CO2 hydrase assay method.2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311032Inhibition of human carbonic anhydrase 122007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID1067228Inhibition of human transmembrane carbonic anhydrase 9 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID50350Inhibition of cloned human cytosolic isozyme Carbonic anhydrase I2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID239126Inhibitory constant against catalytic domain of human carbonic anhydrase XII2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID301578Inhibition of human recombinant CA 3 assessed as CO2 hydration by stopped flow kinetic assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.
AID734184Inhibition of recombinant human carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay2013European journal of medicinal chemistry, Apr, Volume: 62Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship.
AID603071Inhibition of human recombinant cytosolic carbonic anhydrase 13 preincubated for 15 mins by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms.
AID320309Inhibition of human recombinant full length carbonic hydrase 5A by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID367820Inhibition of human recombinant CA1 by stopped-flow CO2 hydrase assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.
AID238084Inhibition constant against human (cloned) isozyme (hCA II) by CO2 hydration method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID238439Inhibition constant against human carbonic anhydrase XI2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
AID272527Inhibition of catalytic domain of human cloned CA12 by stopped-flow CO2 hydration method2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID293814Selectivity for human recombinant CA9 over human recombinant CA22007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties.
AID93581Level in red blood cells after incubation of human erythrocytes for 30 min, was determined by HPLC method2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID256963Inhibitory activity against human recombinant cytosolic CA22005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID238083Inhibition constant against human cloned isozyme (hCA IX) by CO2 hydration method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID261579Inhibition of human recombinant carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID352787Inhibition of human recombinant CA1 by CO2 hydration stopped-flow assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII.
AID408470Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID255389Selectivity is measured as ratio of Ki value of Carbonic anhydrase II to that of Carbonic anhydrase IX2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID311023Inhibition of human carbonic anhydrase 12007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID93582Level in red blood cells after incubation of human erythrocytes for 60 min, was determined by EI method2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID1062684Inhibition of human CA12 after 15 mins by stopped-flow CO2 hydration assay2014European journal of medicinal chemistry, Jan, Volume: 71Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associat
AID328978Inhibition of human full length carbonic anhydrase 5A2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID417835Inhibition of mouse recombinant full length CA13 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID1188135Inhibition of human recombinant Carbonic anhydrase 2 compound preincubated for 15 mins by stopped flow CO2 hydrase assay method2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.
AID239250Inhibitory activity against beta carbonic anhydrase (Cab) from Methanobacterium thermoautotrophicum2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1142837Inhibition of Legionella pneumophilia subsp. Pneumophila strain Philadelphia-1 carbonic anhydrase-2 assessed as CO2 hydrase activity by stopped-flow assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Sulfonamide inhibition studies of two β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID299550Inhibition of Helicobacter pylori alpha CA2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID386504Selectivity for human CA9 over human CA22008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID1278409Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by CO2 hydrase stopped flow assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1067227Inhibition of human transmembrane carbonic anhydrase 12 by stopped-flow CO2 hydration assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.
AID299546Inhibition of human CA9 catalytic domain2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID50177In vitro inhibition of carbonic anhydrase was determined using enzyme prepared from mouse erythrocytes1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides.
AID1194027Inhibition of recombinant Porphyromonas gingivalis gamma-carbonic anhydrase by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID299551Inhibition of Helicobacter pylori beta CA2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID743515Inhibition of human recombinant carbonic anhydrase 1 preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID299548Inhibition of mouse CA132007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies.
AID1262267Inhibition of Chionodraco hamatus alphaCA incubated for 15 mins prior to testing by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Anion and sulfonamide inhibition studies of an α-carbonic anhydrase from the Antarctic hemoglobinless fish Chionodraco hamatus.
AID321157Inhibition of human recombinant CA2 by CO2 hydration stopped flow assay2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID238769Inhibitory activity against Carbonic anhydrase IX2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID1061170Inhibition of Porphyromonas gingivalis gamma-carbonic anhydrase expressed in Escherichia coli preincubated for 15 mins by stopped flow CO2 hydration assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
AID300755Inhibition of human recombinant CA2 by CO2 hydration stopped flow assay2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.
AID578224Inhibition of human recombinant CA5B mitochondrial isoform by stopped-flow CO2 hydration assay2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
(R)-/(S)-10-camphorsulfonyl-substituted aromatic/heterocyclic sulfonamides selectively inhibit mitochondrial over cytosolic carbonic anhydrases.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1275912Inhibition of human Carbonic anhydrase2 using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID271173Inhibition of human recombinant carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID1291363Inhibition of recombinant Vibrio cholerae gamma-carbonic anhydrase preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Comparison of the sulfonamide inhibition profiles of the α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
AID299249Inhibition of Helicobacter pylori alpha carbonic anhydrase by stopped-flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID299242Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.
AID238987Inhibitory activity against human carbonic anhydrase IX at 0.09 uM2004Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24
Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
AID271714Selectivity for human CA9 over CA22006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID316061Inhibition of human recombinant full length carbonic hydrase 2 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID287700Inhibition of human recombinant carbonic anhydrase 9 by CO2 hydration method2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
AID271038Inhibition of human cloned CA2 by CO2 hydration assay2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
AID244240Binding affinity ratio towards human cloned carbonic anhydrase II to that of human cloned carbonic anhydrase IX2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide.
AID47719Compound was evaluated for inhibition against human carbonic anhydrase II2004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX.
AID48091Inhibitory activity against human carbonic anhydrase II.2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates.
AID320307Inhibition of human recombinant full length carbonic hydrase 3 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID577531Inhibition of Brucella suis carbonic anhydrase I by spectrophotometry at pH 8.32011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.
AID238574Inhibitory activity against human carbonic anhydrase II (hCAII)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
AID316067Inhibition of human recombinant full length carbonic hydrase 7 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID311025Inhibition of human carbonic anhydrase 32007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID316066Inhibition of human recombinant full length carbonic hydrase 6 by stopped-flow assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
AID258730Inhibitory activity against cloned human CA22006Bioorganic & medicinal chemistry letters, Jan-15, Volume: 16, Issue:2
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
AID237406Compound level in Red Blood Cells at 60 min, after exposure of 10 mL of Blood to compound solution by HPLC method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID1453410Inhibition of Francisella tularensis beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID275807Inhibition of human recombinant cytosolic isozyme CA I by stopped-flow CO2 hydrase method2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
AID386503Selectivity for human CA9 over human CA12008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID311029Inhibition of human carbonic anhydrase 62007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID50185Evaluated for its activity against carbonic anhydrase (CA) in anesthetized rabbits1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.
AID436565Inhibition of cloned Stylophora pistillata alpha-CA expressed in human HEK293 cells by stopped-flow CO2 assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.
AID50378Inhibitory activity against human carbonic anhydrase I (hCA I)2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide.
AID222127Inhibition of cloned isozyme, human carbonic anhydrase IV2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties.
AID271710Inhibition of human cloned CA1 by CO2 hydration method2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
AID238085Inhibition constant against human (cloned) isozyme (hCA I) by the CO2 hydration method2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
AID238323Inhibitory activity against human Carbonic anhydrase II2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.
AID50373Inhibitory activity against human recombinant carbonic anhydrase I2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Carbonic anhydrase inhibitors: water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects.
AID408474Selectivity for human cloned CA9 over human recombinant CA22008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID486933Inhibition of human cloned carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides.
AID486933Inhibition of human cloned carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID311033Inhibition of mouse carbonic anhydrase 132007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
Carbonic anhydrases as targets for medicinal chemistry.
AID1453412Inhibition of human carbonic anhydrase-1 assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID470873Inhibition of carbonic anhydrase 2 assessed as inhibition of carbon dioxide hydration2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
A QSAR study on relationship between structure of sulfonamides and their carbonic anhydrase inhibitory activity using the eigenvalue (EVA) method.
AID238208Inhibitory constant against human Carbonic anhydrase I2005Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
AID367608Inhibition of human recombinant full length CA1 by stopped-flow CO2 hydration method2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367608Inhibition of human recombinant full length CA1 by stopped-flow CO2 hydration method2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID226919Anticonvulsant potency in mice relative to compound UK-12130 (ED50 of compound 24/compound)1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides.
AID320312Inhibition of human recombinant full length carbonic hydrase 7 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
AID1453411Inhibition of Burkholderia pseudomallei beta-carbonic anhydrase assessed as reduction in CO2 hydration preincubated for 15 mins followed by CO2 addition measured for 10 to 100 secs by stopped-flow assay
AID48310Inhibitory activity against murine carbonic anhydrase XIII (mCA XIII) by using CO2 hydrase assay method2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
AID1140816Inhibition of human carbonic anhydrase 2-catalyzed CO2 hydration preincubated for 10 mins by stopped-flow assay2014Bioorganic & medicinal chemistry, May-15, Volume: 22, Issue:10
Carbonic anhydrase inhibitors. Inhibition of human cytosolic isoforms I and II with (reduced) Schiff's bases incorporating sulfonamide, carboxylate and carboxymethyl moieties.
AID93584Level in red blood cells after incubation of human erythrocytes for 60 min, was determined by HPLC method2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID232688Selectivity ratio of KI, human carbonic anhydrase II (hCA II), to that of KI, mouse carbonic anhydrase V (mCA V)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID20925Compound was evaluated for its solubility in water1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.
AID459696Inhibition of Brucella suis CA1 expressed in Escherichia coli BL21(DE3) by stopped-flow CO2-hydration assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.
AID1593065Inhibition of full length human CA 12019European journal of medicinal chemistry, Apr-15, Volume: 168Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID1347711Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydration assay
AID369274Inhibition of human recombinant carbonic anhydrase 9 catalytic domain by stopped flow CO2 hydrase assay2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID256965Inhibitory activity against human recombinant mitochondrial isozyme CA VB2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1287519Inhibition of Vibrio cholerae beta carbonic anhydrase incubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.
AID1628037Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stop flow CO2 hydrase assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Cloning, expression, purification and sulfonamide inhibition profile of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID27591Partition coefficient (logD) (chloroform/buffer)2000Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23
Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action.
AID287699Inhibition of human recombinant carbonic anhydrase 2 by CO2 hydration method2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
AID437750Inhibition of full length Mycobacterium tuberculosis H37Rv recombinant carbonic anhydrase 2 encoded by RV3588c by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
AID281086Selectivity ratio of human CA9 over human CA22007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID321160Selectivity for human CA9 over human CA12008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of the tumor-associated isoforms IX and XII.
AID1347714Inhibition of human carbonic anhydrase 12 by stopped-flow CO2 hydration assay
AID770582Inhibition of human membrane bound carbonic anhydrase 12 preincubated for 15 mins at room temperature followed by 72 hrs at 4 degC by stopped flow CO2 hydration assay2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1194024Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydrase assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the Antarctic cyanobacterium Nostoc commune.
AID254241Inhibitory activity against human cloned Carbonic anhydrase II by the CO2 hydration method2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
AID195094Inhibitor level was measured in red blood cells at 60 min after exposure of 10 mL of blood to solutions by enzymatic method (EI)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes.
AID417828Inhibition of human recombinant full length CA4 by stopped flow CO2 hydration assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases.
AID614105Inhibition of human cloned carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives.
AID669115Inhibition of human carbonic anhydrase 2 preincubated for 15 mins measured for 10 to 100 sec by stopped-flow method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.
AID1275911Inhibition of Vibrio cholerae alpha-carbonic anhydrase using CO2 as substrate preincubated for 15 mins by stopped-flow CO2 hydration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID328976Inhibition of human full length carbonic anhydrase 32008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID743512Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 recombinant carbonic anhydrase preincubated for 15 mins by CO2 hydration stopped-flow assay2013Bioorganic & medicinal chemistry, Mar-15, Volume: 21, Issue:6
The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.
AID118612Anticonvulsant activity in mice by MES test at 3.0 hr following intraperitoneal injection of 30 mg/kg dose.2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
AID1593067Inhibition of human CA 9 catalytic domain2019European journal of medicinal chemistry, Apr-15, Volume: 168Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID711662Selectivity ratio of Ki for human CA2 to Ki for human CA92012European journal of medicinal chemistry, Oct, Volume: 56Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.
AID48302Inhibitory activity against human carbonic anhydrase IX2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1796755CA Inhibition Assay from Article 10.1021/jm021123s: \\Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.\\2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives.
AID1799673CA Assay from Article 10.1080/14756360410001689559: \\Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor.\\2004Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 19, Issue:3
Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor.
AID1796980CA Inhibition Assay from Article 10.1021/jm060807n: \\Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide anal2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.
AID1799734Inhibition Assay from Article 10.1080/14756360802218441: \\Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast ca2009Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 24, Issue:2
Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines.
AID1799266CA Inhibition Assay from Article 10.1016/j.bmc.2009.05.002: \\Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.\\2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.
AID1797528Esterase Assay from Article 10.1021/jm031057+: \\Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.\\2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID1797360CA Inhibition Assay from Article 10.1021/jm061320h: \\Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.\\2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides.
AID1796552CA Inhibition Assay from Article 10.1021/jm0512600: \\Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.\\2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.
AID1797276Esterase Assay from Article 10.1021/jm031079w: \\Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.\\2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX.
AID1796855CA Inhibition Assay from Article 10.1021/jm0494826: \\Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.\\2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
AID1796595CA Inhibition Assay from Article 10.1021/jm060531j: \\Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.\\2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX.
AID1796582CA Inhibition Assay from Article 10.1021/jm050483n: \\Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.\\2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
AID1798598CA Inhibition Assay from Article 10.1016/j.bmcl.2008.03.051: \\Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.\\2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1796686CA Inhibition Assay from Article 10.1016/s0968-0896(00)00026-2: \\2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit.\\2000Bioorganic & medicinal chemistry, May, Volume: 8, Issue:5
2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit.
AID1799586Inhibition Assay from Article 10.1111/j.1747-0285.2009.00842.x: \\Carbonic anhydrase inhibitors: inhibition of cytosolic carbonic anhydrase isozymes II and VII with simple aromatic sulfonamides and some azo dyes.\\2009Chemical biology & drug design, Aug, Volume: 74, Issue:2
Carbonic anhydrase inhibitors: inhibition of cytosolic carbonic anhydrase isozymes II and VII with simple aromatic sulfonamides and some azo dyes.
AID1798769CA Inhibition Assay from Article 10.1021/jm801267c: \\Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.\\2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.
AID1799511Enzymatic Assay from Article 10.1016/j.chembiol.2006.05.008: \\MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells.\\2006Chemistry & biology, Jul, Volume: 13, Issue:7
MASPIT: three-hybrid trap for quantitative proteome fingerprinting of small molecule-protein interactions in mammalian cells.
AID1798985CA Inhibition Assay from Article 10.1021/jm9000488: \\Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.\\2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
AID1798982CA Inhibition Assay from Article 10.1021/jm9003126: \\Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1345957Human carbonic anhydrase 14 (4.2.1.1 Carbonate dehydratases)2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID1345928Human carbonic anhydrase 1 (4.2.1.1 Carbonate dehydratases)2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID1346202Human carbonic anhydrase 7 (4.2.1.1 Carbonate dehydratases)2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.
AID1345928Human carbonic anhydrase 1 (4.2.1.1 Carbonate dehydratases)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1346210Human carbonic anhydrase 12 (4.2.1.1 Carbonate dehydratases)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
AID1346003Human carbonic anhydrase 4 (4.2.1.1 Carbonate dehydratases)2005Bioorganic & medicinal chemistry letters, Sep-01, Volume: 15, Issue:17
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (450)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990112 (24.89)18.7374
1990's65 (14.44)18.2507
2000's140 (31.11)29.6817
2010's111 (24.67)24.3611
2020's22 (4.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.55 (24.57)
Research Supply Index6.17 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index97.28 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (57.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (5.04%)5.53%
Reviews14 (3.07%)6.00%
Case Studies28 (6.14%)4.05%
Observational0 (0.00%)0.25%
Other391 (85.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Stop Retinal Ganglion Cell Dysfunction Study [NCT02390284]Phase 3500 participants (Anticipated)Interventional2015-09-30Active, not recruiting
Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance [NCT05575180]Phase 415 participants (Anticipated)Interventional2023-08-11Recruiting
The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue. [NCT02758470]Phase 413 participants (Actual)Interventional2016-11-30Completed
Use of Methazolamide to Lower Intraocular Pressure [NCT05498103]Phase 430 participants (Anticipated)Interventional2023-01-01Recruiting
The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia [NCT02760121]Phase 414 participants (Actual)Interventional2016-05-31Completed
Improving Tumor Oxygenation in Cervical Cancer With Methazolamide [NCT00257829]Phase 20 participants (Actual)Interventional2004-07-31Withdrawn(stopped due to This study was closed due to lack of funding.)
The Safety Evaluation of Aminophylline and Methazolamide When Administered Orally Alone and in Combination to Healthy Volunteers [NCT01587027]Phase 116 participants (Actual)Interventional2011-12-31Completed
Three New Ideas to Protect Special Forces From the Stress of High Altitude [NCT02463357]Phase 4148 participants (Actual)Interventional2015-08-31Completed
Rapid Acclimatization to Hypoxia at Altitude [NCT01702025]Phase 1/Phase 241 participants (Actual)Interventional2012-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01587027 (1) [back to overview]Adverse Events.
NCT01702025 (1) [back to overview]Magnitude of Decrement in Exercise Time Trial Performance in Hypoxia (Low Oxygen) Compared With Normoxia (Normal Oxygen).
NCT02463357 (5) [back to overview]Change in Uphill Hike at High Altitude
NCT02463357 (5) [back to overview]Change in Army Physical Fitness Test (APFT) at High Altitude
NCT02463357 (5) [back to overview]Change in Defense Automated Neurobehavioral Assessment (DANA) Reaction Time at High Altitude
NCT02463357 (5) [back to overview]Change in Environmental Symptoms Questionnaire at High Altitude
NCT02463357 (5) [back to overview]Change in Lake Louise AMS Scoring System at High Altitude

Adverse Events.

Adverse event data was evaluated for incidence and severity for 6 days. (NCT01587027)
Timeframe: 6 days.

InterventionEvents (Number)
Sequence A29
Sequence B40

[back to top]

Magnitude of Decrement in Exercise Time Trial Performance in Hypoxia (Low Oxygen) Compared With Normoxia (Normal Oxygen).

After exercising on a stationary cycle ergometer for 30 minutes at a resistance of 100 watts, research participants will complete an exercise time trial. The time taken to cycle a distance equivalent to 7.75 miles will be recorded. On a separate day the experiment will be repeated in hypoxia. It is expected that the time taken to cycle a distance equivalent to 7.75 miles will be longer in hypoxia compared to normoxia. One of the goals of this research is to determine if the hypoxia-mediated performance decrement can be decreased with one of our pharmacological interventions. (NCT01702025)
Timeframe: The exercise trial will begin within 5 hours of exposure to either normoxia or hypoxia

Interventionminutes (Mean)
Normoxia Placebo22.3
Hypoxia Placebo25.2
Normoxia Aminophylline22.2
Hypoxia Aminophylline24.0
Normoxia Methazolamide23.0
Hypoxia Methazolamide24.6
Normoxia Methazolamide/Aminophylline24.5
Hypoxia Methazolamide/Aminophylline25.9

[back to top]

Change in Uphill Hike at High Altitude

Timed 3.1 mile uphill run/hike, with weighted back-pack (NCT02463357)
Timeframe: 2nd day at altitude

Interventionseconds (Mean)
Quercetin4685
Nifedipine+Methazolamide4993
Metformin5005
Placebo4819
Nitrite4953

[back to top]

Change in Army Physical Fitness Test (APFT) at High Altitude

"Timed 2 mile run, push-ups, sit-ups, and pull-ups. The Army Physical Fitness Test (APFT) measures physical fitness. Higher scores indicate a better outcome. A score of 60 is considered minimum passing score. The maximum possible score is 300, indicating the highest level of physical fitness." (NCT02463357)
Timeframe: Baseline, 1st day at high altitude

,,,,
Interventionscore on a scale (Mean)
BaselineChange at Day 1
Metformin254.1-32.9
Nifedipine+Methazolamide251.0-59.2
Nitrite252.1-26.1
Placebo251.5-23.0
Quercetin247.2-27.5

[back to top]

Change in Defense Automated Neurobehavioral Assessment (DANA) Reaction Time at High Altitude

Battery of nine cognitive function tests. The Defense Automated Neurobehavioral Assessment (DANA) measures cognitive function and was used to measure mean reaction time. Possible scores range from 180 to 500 milliseconds, with lower scores indicating a better outcome. (NCT02463357)
Timeframe: Baseline and and 1st day at high altitude

,,,,
Interventionmilliseconds (Mean)
BaselineChange from baseline at day 1
Metformin312.3-8.3
Nifedipine+Methazolamide302.214.2
Nitrite310.7-4.6
Placebo333.90.5
Quercetin308.0-0.5

[back to top]

Change in Environmental Symptoms Questionnaire at High Altitude

Self-reported assessment of AMS symptoms (headache, lightheaded, dizzy, etc.). The 11-item Environmental Symptoms Questionnaire measures Acute Mountain Sickness symptoms (nausea, weakness, lightheadedness, dizziness, headache, etc.). Possible scores range from 0 to 55 (0-5 per item), with higher scores indicating a better outcome. (NCT02463357)
Timeframe: Baseline and during high altitude exposure (3 days, AM/PM)

,,,,
Interventionscore on a scale (Mean)
BaselineChange at 3 days
Metformin0.0800.128
Nifedipine+Methazolamide0.122-0.073
Nitrite0.1210.044
Placebo0.0690.035
Quercetin0.132-0.088

[back to top]

Change in Lake Louise AMS Scoring System at High Altitude

Self-reported assessment of AMS symptoms (headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping). The Lake Louise AMS Scoring System measures symptoms of altitude sickness. Possible scores range from 0 to 16, with higher scores indicating a worse outcome. (NCT02463357)
Timeframe: Baseline and during high altitude exposure (3 days, AM/PM)

,,,,
Interventionscore on a scale (Mean)
BaselineChange at Day 3
Metformin0.1500.750
Nifedipine+Methazolamide0.1500.150
Nitrite0.2500.474
Placebo0.000.632
Quercetin0.000.053

[back to top]